Antibodies against myelin oligodendrocyte glycoprotein were the most frequently encountered antibody in autoimmune encephalitis.
To characterize myelin oligodendrocyte glycoprotein (MOG) antibody–associated demyelinating and encephalic pediatric syndromes, investigators in Spain conducted a prospective, observational study of 535 children with central nervous system disorders consistent with acute disseminated encephalomyelitis (ADEM), neuromyelitis optica spectrum disorders (NMOSD), non-ADEM encephalitis, and other demyelinating disorders (e.g., transverse myelitis and optic neuritis).
Of 239 children with demyelinating syndromes, 94 (39%) were MOG antibody positive, including 3 of 43 (7%) with multiple sclerosis. Of the 64 children with non-ADEM encephalitis, 22 (34%) were MOG antibody positive. Of the 116 MOG antibody–positive patients, 49% were girls, median age w…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)